Adds global particle size technology leader to its bioavailability and delivery technology offerings
Catalent, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has acquired Micron Technologies. Catalent will add Micron Technologiesí superior particle size engineering capabilities to its industry-leading suite of drug delivery and development solutions.
Catalent can now partner with more pharmaceutical innovators at the earliest stages of the drug development process with a set of options and expertise ranging from OptiForm API optimisation and Micron Technologies particle size optimisation, to expert formulation and final dose form design services, through to bioavailability solutions such as RP Scherer Softgel lipid systems and OptiMelt hot melt extrusion technologies.
'This strategic acquisition allows Catalent to provide an unprecedented set of integrated development solutions and superior drug delivery technologies to the industry, partnering with our customersí R&D teams earlier in the development cycle and helping them deliver better treatments to clinic and to market faster and more efficiently,' said John Chiminski, Catalent President and CEO. 'We are pleased to add Micron Technologiesí leading technologies and manufacturing expertise and welcome their highly talented management, scientific and operations teams to Catalent.'
Micron Technologies adds to Catalentís long history of innovation and leadership in the pharmaceutical industry, with its proven and versatile portfolio of particle size reduction, micronisation and milling technologies used to overcome bioavailability, stability and manufacturability challenges.
The company currently operates two state-of-the-art facilities in Malvern, PA, and in Dartford, UK, and employs approximately 100 people across both sites. It is capable of processing R&D and commercial volumes at both of its sites. Micron Technologies currently supports active programmes involving more than 300 customers from around the world. Both facilities are equipped with advanced systems to ensure the quality, safety and total containment of highly potent and cytotoxic compounds, and provide integrated analytical services capabilities from early stage development to commercialisation.
'We are excited to become part of Catalent, as there is a natural synergy between our organisations,' said Joseph Drost, CEO of Micron Technologies, who will continue to lead this business. 'Through access to Catalentís global network, development expertise and innovative technologies, we can jointly provide end-to-end solutions to accelerate drug development programmes and bring better treatments to patients worldwide.'
The acquisition is Catalentís second since its IPO in July, and follows the acquisition of Redwood Bioscience, with its SMARTag Antibody-Drug Conjugate (ADC) technology platform, in October 2014.